Medical Marijuana Inc (OTCMKTS:MJNA) reported that Raúl Elizalde, the President of its subsidiary unit HempMeds® Mexico, was featured in several global news publications about his communication engagement at the WHO Drug Scheduling Event on Psychotropic Substances in last month.
Elizalde, who led campaign to assist his epileptic daughter legalized CBD in Mexico, talked on how the CBD is non-addictive, non-psychoactive and has no adverse side effects. He revealed his story about how Cannabidiol changed his family’s life for the good and how the WHO’s recommendation has the prospect to transform many more lives across the world.
News publications Elizalde got showcased in include The Daily Mail, WestWord newspapers, The Georgia Straight Vancouver, New Zealand Herald, Metro UK, Bustle, India.com, Newburgh Gazette and TeleSur TV. Dr. Stuart Titus, the CEO of Medical Marijuana, reported that they are extremely delighted and proud to have Elizalde representing the company portfolio of firms and to have their objective of increasing access to Cannabidiol featured in coverage on such leading media outlets.
They consider that Elizalde had a notable impact on the WHO’s recommendation not to schedule Cannabidiol and they are thankful that the media remains to consider him as a notable cannabis industry icon. Medical Marijuana continues to be a pioneer for the industry, and the upcoming period is extremely bright indeed.
HempMeds® Mexico marks as a Mexico-based firm that made history by being the introductory firm to get a COFEPRIS federal government import license for the cannabis offering RSHO-X™ for a medical indication. It intends to work with the Mexican government to legally and safely offer access to Cannabidiol hemp oil products.
In the last trading session, the stock price of Medical Marijuana declined more than 2% to close the day at $0.1021. The decline came at a share volume of 11.77 million compared to average share volume of 9.44 million.